Differential progression-free survival (PFS) to erlotinib according to EGFR exon 19 deletion type in non-small cell lung cancer (NSCLC) patients (p) in the EURTAC study.
Enric Carcereny Costa
No relevant relationships to disclose
Miquel Taron
No relevant relationships to disclose
Cristina Queralt
No relevant relationships to disclose
Itziar de Aguirre
No relevant relationships to disclose
Laia Capdevila
No relevant relationships to disclose
Sara Cros
No relevant relationships to disclose
Alain Vergnenegre
No relevant relationships to disclose
Filippo De Marinis
No relevant relationships to disclose
Bartomeu Massuti
No relevant relationships to disclose
Noemi Reguart
No relevant relationships to disclose
Mayumi Ono
No relevant relationships to disclose
Cristina Buges
No relevant relationships to disclose
Mariano Provencio
No relevant relationships to disclose
Pilar Garrido López
No relevant relationships to disclose
Santiago Viteri Ramirez
No relevant relationships to disclose
Amaya Gasco
No relevant relationships to disclose
Jose Miguel Sanchez
No relevant relationships to disclose
Manuel Cobo
No relevant relationships to disclose
Ana Drozdowskyj
No relevant relationships to disclose
Rafael Rosell
No relevant relationships to disclose